Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats

Pharmacology Biochemistry and Behavior

Volumn 97, Issue 1, 2010, Pages 92-100

  Tallett, A J ^a   Blundell, J E ^a   Rodgers, R J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Behavioural satiety sequence; Feeding behaviour; Food intake; Low doses; Monotherapy; Polytherapy; Rats; Rimonabant; Sibutramine

Indexed keywords

NALOXONE; RIMONABANT; SIBUTRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APPETITE; ARTICLE; BEHAVIOURAL SATIETY SEQUENCE; DRUG EFFECT; FEEDING BEHAVIOR; FOOD INTAKE; GROOMING; HABITUATION; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; RAT; SCRATCHING; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; APPETITE; CYCLOBUTANES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; MALE; PIPERIDINES; PYRAZOLES; RATS; REACTION TIME; SATIETY RESPONSE; WEIGHT GAIN;

RATTUS; RODENTIA;

EID: 77957752999     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.12.010     Document Type: Article

References (92)

1. Adan R.A.H., Vanderschuren L.J.M.J., la Fleur S.E. Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci 2008, 29:208-217.
2. Bays H., Dujovne C. Anti-obesity drug development. Exp Opin Investig Drugs 2002, 11:1189-1204.
3. Berendsen H.H.G., Broekkamp C.L.E. A peripheral 5-HT1D-like receptor involved in serotonergic induced hindlimb scratching in rats. Eur J Pharmacol 1991, 194:201-208.
4. Berendsen H.H.G., Broekkamp C.L.E., van Delft A.M.L. Possible involvement of 5HT1D receptors in drug-induced hindlimb scratching in rats. European Eur J Pharmacol 1990, 183:1924-2925.
5. Bhavsar S., Watkins J., Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 2004, 81:781-793.
6. Blundell J.E., Halford J.C.G. Serotonin and appetite regulation: implications for the treatment of obesity. CNS Drugs 1998, 9:473-495.
7. 1A receptors are involved in the anxiolytic effect of Δ-9 tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 2007, 555:156-163.
8. Bray G.A., Greenway F.L. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007, 59:151-184.
9. Casado A., Rodriguez V.M., Portillo M.P., Macarulla M.T., Abecia L.C., Echevarria E., et al. Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins. Nutr Neurosci 2003, 6:103-111.
10. Chiesi M., Huppertz C., Hofbauer K.G. Pharmacotherapy of obesity: targets and perspectives. Trends Pharmacol Sci 2001, 22:247-254.
11. Clapham J.C., Arch J.R.S., Tadayyon M. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmac Ther 2001, 89:81-121.
12. Collins P., Williams G. Drug treatment of obesity: from past failures to future successes?. Br J Clin Pharmac 2001, 51:13-25.
13. Connoley I.P., Liu Y.-L., Frost I., Reckless I.P., Heal D.J., Stock M.J. Thermogenic effects of sibutramine and its metabolites. Brit J Pharmacol 1999, 126:1487-1495.
14. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
15. Darmani N.A., Pandya D.K. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naïve mice. J Neural Transm 2000, 107:931-945.
16. DiMarzo V. CB1 receptor antagonism: biological basis for metabolic effects. Drug Discovery Today 2008, 13:1026-1041.
17. Eison A.S., Wright R.N., Freeman R. Peripheral 5-carboxamidotryptamine induces hindlimb scratching by stimulating 5-HT1A receptors in rats. Life Sci 1992, 51:95-99.
18. Fjellner B., Hägermark Ö. Pruritis in polycythemia vera: treatment with aspirin and possibility of platelet involvement. Acta Derm Venereol 1979, 59:505-512.
19. Fontaine K.R., Redden D.T., Wang C., Westfall A.O., Allison D.B. Years of life lost due to obesity. JAMA 2003, 289:187-193.
20. Garfield A.S., Heisler L.K. Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol 2009, 587:49-60.
21. Golozoubova V., Strauss F., Malmlöf K. Locomotion is the major determinant of sibutramine-induced increase in energy expenditure. Pharmacol Biochem Behav 2006, 83:517-527.
22. Greenway F.L., Whitehouse M.J., Guttadauria M., Anderson J.W., Atkinson R.L., Fujioka K., et al. Rational design of a combination medication for the treatment of obesity. Obesity 2009, 17:30-39.
23. Grignaschi G., Fanelli E., Scagnol I., Samanin R. Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats. Brit J Pharmacol 1999, 127:1190-1194.
24. Halford J.C.G., Cooper G.D., Dovey T.M., Ishii Y., Rodgers J., Blundell J.E. The psychopharmacology of appetite: targets for potential anti-obesity agents. Curr Med Chem: CNS Agents 2003, 3:283-310.
25. Halford J.C.G., Heal D.J., Blundell J.E. Effects in the rat of sibutramine on food intake and the behavioural satiety sequence. Brit J Pharmacol 1995, 114:387P.
26. Halford J.C.G., Wanninayake S.C.D., Blundell J.E. Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 1998, 61:159-168.
27. Haring M., Marsicano G., Lutz B. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 2007, 146:1212-1219.
28. Hermann H., Marsicano G., Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002, 109:451-460.
29. Hewitt K.N., Lee M.D., Dourish C.T., Clifton P.T. Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 2002, 71:691-700.
30. Hill M.N., Gorzalka B.B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav Pharmacol 2005, 16:333-352.
31. Ishii Y., Blundell J.E., Halford J.C.G., Rodgers R.J. Effects of systematic variation in presatiation and fasting on the behavioural satiety sequence in male rats. Physiol Behav 2003, 79:227-238.
32. Jackson H.C., Needham A.M., Hutchins L.J., Mazurkiewicz S.E., Heal D.J. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Brit J Pharmacol 1997, 121:1758-1762.
33. 1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 2002, 73:911-919.
34. Jarbe T.U.C., Ross T., DiPatrizion N.V., Pandarinathan L., Makriyannis A. Effects of CB1R agonist WIN-55, 212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. Pharmacol Biochem Behav 2006, 85:243-252.
35. Kaya A., Aydin N., Topsever O., Filiz M., Ozturk A., Dagar A., et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004, 58:582-587.
36. Kelaï S., Hanoun N., Aufrère G., Beaugé F., Hamon M., Lanfumey L. Cannabinoid-serotonin interactions in alcohol-preferring vs. alcohol-avoiding mice. J Neurochem 2006, 99:308-320.
37. 2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 1997, 36:233-239.
38. Kimura T., Ohta T., Watanabe K., Yoshimura H., Yamamoto I. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol Pharm Bull 1998, 21:224-226.
39. Kirkham T.C. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiat 2009, 21:163-171.
40. Kirkham T.C., Williams C.M. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology 2001, 153:267-270.
41. Korner J., Aronne L.J. Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocr Metab 2004, 89:2616-2621.
42. Kuraishi Y., Yageta Y., Konno M., Andoh T., Yamaguchi-Miyamoto T., Nojima H. Intracisternal, but not intrathecal, injection of naloxone inhibits cutaneous itch-related response in mice. Biol Pharmaceut Bull 2008, 31:2143-2145.
43. 1 receptor is expressed on serotonergic and dopaminergic neurons. Eur J Pharmacol 2008, 578:137-141.
44. Luque C.A., Rey J.A. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002, 440:119-128.
45. 9-tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat. Brit J Pharmacol 1998, 124:1419-1424.
46. 9-tetrahydrocannabinol-induced hypothermia in the rat. Pharmacol Biochem Behav 2001, 69:595-601.
47. Marco E.M., Pérez-Alvarez L., Borcel E., Rubio M., Guaza C., Ambrosio E., et al. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55, 940 in male rats. Behav Pharmacol 2004, 15:21-27.
48. 2A/C receptors. J Neurochem 2007, 103:2111-2120.
49. McNeely W., Goa K.L. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998, 56:1093-1124.
50. Mokdad A.H., Serdula M.K., Dietz W.H., Bowman B.B., Marks J.S., Koplan J.P. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999, 282:1519-1522.
51. 9-tetrahydrocannabinol treatments. Neurochem Res 1993, 18:1183-1191.
52. Moranta D., Esteban S., Garcia-Sevilla J.A. Ethanol desensitizes cannabinoid CB1 receptors modulating monoamine synthesis in the rat brain in vivo. Neurosci Letts 2006, 392:58-61.
53. 1 receptors. Naunyn Schmiedebergs Arch Pharmacol 2000, 361:19-24.
54. National Audit Office Tackling obesity in England 2001, Auditor General, HMSO, Norwich, UK National Audit Office.
55. 7-36 inhibit food intake additively. Endocrinology 2005, 146:5120-5127.
56. NIH Obesity Research Task Force 2004. http://www.obesityresearch.nih.gov.
57. Nisoli E., Carruba M.O. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obesity Revs 2000, 1:127-139.
58. Nissen S.E., Nicholls S.J., Wolski K., Rodes-Cabau J., Cannon C.P., Deanfield J.E., et al. Effect of rimonabant on progression of athersclerosis in patients with abdominal obesity and coronary heart disease: the STRADIVARIUS randomised controlled trial. JAMA 2008, 299:1547-1560.
59. Padwal R.S., Li S.K., Lau D.C.W. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized control trials. Int J Obesity 2003, 27:1437-1446.
60. Padwal R.S., Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine and rimonabant. Lancet 2007, 369:71-77.
61. Pi-Sunyer F.X. Medical hazards of obesity. Ann Intern Med 1993, 119:655-660.
62. 3 receptors in vivo. Eur J Pharmacol 2008, 596:98-101.
63. Rennie K.L., Jebb S.A. Prevalence of obesity in Great Britain. Obesity Revs 2005, 6:11-12.
64. Rodgers RJ, Halford JCG, Nunes de Souza RL, Canto de Souza AL, Piper DC, Arch JRS, et al. SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur J Neurosci 2001;13:1444-52.
65. [3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 2007, 148:6054-6061.
66. Roth J.D., Rowland N.E. Anorectic efficacy of the fenfluramine/phenteramine combination in rats: additivity or synergy. Eur J Pharmacol 1999, 373:127-134.
67. Roth J.D., Trevaskis J.L., Wilson J., Lei C., Athanacio J., Mack C., et al. Antiobesity effects of the beta-cell hormone amylin in combination with phenteramine or sibutramine in diety-induced obese rats. Int J Obesity 2008, 32:1201-1210.
68. Rowland N.E., Mukherjee M., Robertson K. Effects of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 2001, 159:111-116.
69. Simansky K.J. Serotonergic control of the organization of feeding and satiety. Behav Brain Res 1996, 73:37-42.
70. Ständer S., Böckenholt B., Schürmeyer-Horst F., Weishaupt C., Heuft G., Luger T.A., et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009, 89:45-51.
71. 1 receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. Eur J Pharmacol 2008, 589:149-156.
72. Tallett A.J., Blundell J.E., Rodgers R.J. Acute anorectic response to cannabinoid receptor antagonist/inverse agonist AM 251 in rat: indirect behavioural mediation. Behav Pharmacol 2007, 18:591-600.
73. Tallett A.J., Blundell J.E., Rodgers R.J. Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology 2007, 195:27-39.
74. Tallett A.J., Blundell J.E., Rodgers R.J. Behaviourally-selective hypophagic effects of naloxone in non-deprived male rats presented with palatable food. Behav Brain Res 2008, 187:417-427.
75. Tallett A.J., Blundell J.E., Rodgers R.J. Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching. Physiol Behav 2008, 94:422-431.
76. Tallett A.J., Blundell J.E., Rodgers R.J. Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats. Pharmacol Biochem Behav 2009, 91:358-366.
77. Tallett A.J., Blundell J.E., Rodgers R.J. Night & day: diurnal differences in the behavioural satiety sequence in male rats. Physiol Behav 2009, 97:125-130.
78. Tallett A.J., Blundell J.E., Rodgers R.J. Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats. Behav Brain Res 2009, 198:359-365.
79. Tallett AJ, Blundell JE, Rodgers RJ. Sibutramine & naloxone: infra-additive interaction in the regulation of appetite? Behav Brain Res. 2010;174-81.
80. 3-36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005, 146:3748-3756.
81. Thavanathan R., Volkoff H. Effects of amylin on feeding of goldfish: interactions with CCK. Regulat Peptides 2006, 133:90-96.
82. 1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Brit J Pharmacol 2003, 138:544-553.
83. 1 receptors. Neuropharmacology 2004, 46:966-973.
84. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
85. Vemuri V.K., Janero D.R., Makriyannis A. Therapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav 2008, 93:671-686.
86. 2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. J Pharmacol Exp Ther 2008, 325:567-576.
87. Wellman P.J., Tow S., McMahon L. Isobolographic assessment of the effects of combinations of phenylpropanolamine and fenfluramine on food intake in rats. Pharamcol Biochem Behav 1995, 50:287-291.
88. Weiss SM. Pharmacological and behavioural examination of the defensive reactions of laboratory mice to the calls of the Tawny owl. PhD thesis, 1995, School of Psychology, University of Leeds.
89. 3) receptor antagonist reduce experimentally-induced itch. Inflamm Res 1997, 46:412-416.
90. Wessinger W.D. Approaches to the study of drug interactions in behavioral pharmacology. Neurosci Biobehav Revs 1986, 10:103-113.
91. 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 2002, 71:341-348.
92. World Health Organisation Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO Technical Report Series No. 84 2000, ISBN 92 4 120894